| Literature DB >> 29330365 |
Eduardo Reátegui1,2,3,4,5,6, Kristan E van der Vos7,8, Charles P Lai7,9, Mahnaz Zeinali1,2,3,4, Nadia A Atai7, Berent Aldikacti1,2,4, Frederick P Floyd1,2,3, Aimal H Khankhel1,2,3, Vishal Thapar4, Fred H Hochberg10, Lecia V Sequist4,11, Brian V Nahed4,12, Bob S Carter10, Mehmet Toner1,2,3,5, Leonora Balaj7, David T Ting4, Xandra O Breakefield7,13, Shannon L Stott14,15,16,17,18,19.
Abstract
Extracellular vesicles (EVs) carry RNA, DNA, proteins, and lipids. Specifically, tumor-derived EVs have the potential to be utilized as disease-specific biomarkers. However, a lack of methods to isolate tumor-specific EVs has limited their use in clinical settings. Here we report a sensitive analytical microfluidic platform (EVHB-Chip) that enables tumor-specific EV-RNA isolation within 3 h. Using the EVHB-Chip, we achieve 94% tumor-EV specificity, a limit of detection of 100 EVs per μL, and a 10-fold increase in tumor RNA enrichment in comparison to other methods. Our approach allows for the subsequent release of captured tumor EVs, enabling downstream characterization and functional studies. Processing serum and plasma samples from glioblastoma multiforme (GBM) patients, we can detect the mutant EGFRvIII mRNA. Moreover, using next-generation RNA sequencing, we identify genes specific to GBM as well as transcripts that are hallmarks for the four genetic subtypes of the disease.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29330365 PMCID： PMC5766611 DOI： 10.1038/s41467-017-02261-1
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919